Loading...
XNASATEC
Market cap1.41bUSD
Jan 10, Last price  
9.97USD
1D
3.21%
1Q
93.59%
Jan 2017
210.59%
IPO
13.94%
Name

Alphatec Holdings Inc

Chart & Performance

D1W1MN
XNAS:ATEC chart
P/E
P/S
2.93
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
27.98%
Rev. gr., 5y
39.38%
Revenues
482m
+37.45%
17,821,34542,325,69774,005,00080,031,000101,313,000132,156,000171,610,000197,711,000196,278,000204,724,000206,980,000185,279,000120,248,000101,739,00091,694,000113,427,000144,861,000243,212,000350,867,000482,262,000
Net income
-187m
L+22.67%
509,454-14,054,177-25,816,000-20,202,000-29,288,000-13,289,000-14,355,000-22,181,000-15,459,000-82,227,000-12,882,000-178,676,000-30,317,000-2,294,000-28,975,000-56,902,000-78,994,000-144,326,000-152,149,000-186,638,000
CFO
-78m
L+4.45%
1,281,774-8,239,246-8,593,000-13,237,000-19,479,000-5,548,000-14,833,00013,408,00011,593,0007,807,000-20,271,00010,124,000-9,959,000-8,729,000-25,608,000-33,121,000-46,412,000-73,432,000-75,143,000-78,485,000
Earnings
Feb 25, 2025

Profile

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
482,262
37.45%
350,867
44.26%
Cost of revenue
242,174
161,841
Unusual Expense (Income)
NOPBT
240,088
189,026
NOPBT Margin
49.78%
53.87%
Operating Taxes
(277)
140
Tax Rate
0.07%
NOPAT
240,365
188,886
Net income
(186,638)
22.67%
(152,149)
5.42%
Dividends
Dividend yield
Proceeds from repurchase of equity
212,117
(6,082)
BB yield
-11.58%
0.48%
Debt
Debt current
12,126
19,790
Long-term debt
563,548
380,915
Deferred revenue
2,561
3,047
Other long-term liabilities
8,642
32,099
Net debt
354,704
316,009
Cash flow
Cash from operating activities
(78,485)
(75,143)
CAPEX
(80,508)
(58,280)
Cash from investing activities
(141,975)
(58,280)
Cash from financing activities
356,919
31,228
FCF
159,632
166,768
Balance
Cash
220,970
84,696
Long term investments
Excess cash
196,857
67,153
Stockholders' equity
(1,103,668)
(921,550)
Invested Capital
1,763,428
1,313,891
ROIC
15.62%
13.11%
ROCE
36.39%
48.18%
EV
Common stock shares outstanding
121,242
103,373
Price
15.11
22.35%
12.35
8.05%
Market cap
1,831,967
43.50%
1,276,657
16.11%
EV
2,210,274
1,616,269
EBITDA
299,770
232,954
EV/EBITDA
7.37
6.94
Interest
16,641
5,505
Interest/NOPBT
6.93%
2.91%